NCT05501483View on ClinicalTrials.gov

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

December 31, 2032

Conditions
Type 2 Diabetes
Interventions
DRUG

Pioglitazone 45 mg

Starts with 45 mg

DRUG

Empagliflozin 25 MG

Starts with 25 mg

DRUG

Semaglutide 7 MG

Starts with 3 mg daily for the first 2 weeks

Trial Locations (1)

14186

RECRUITING

Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

lead

Karolinska Institutet

OTHER

NCT05501483 - Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes | Biotech Hunter | Biotech Hunter